Cargando…

How to deprescribe esketamine in resistant depression? A point of view after first clinical uses

Detalles Bibliográficos
Autores principales:	Taillefer de Laportalière, T., Yrondi, A., Jullien, A., Cestac, P., Montastruc, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786612/ https://www.ncbi.nlm.nih.gov/pubmed/35012701 http://dx.doi.org/10.1017/S204579602100072X

Ejemplares similares

Is (S)-norketamine an alternative antidepressant for esketamine?
por: Hashimoto, Kenji, et al.
Publicado: (2018)

How effective are ketamine or esketamine in treatment-resistant depression?
por: Veluri, N., et al.
Publicado: (2021)

Deprescribing in old people: Only for chronic medication?
por: Llor, Carl, et al.
Publicado: (2022)

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

Esketamine hydrochloride for treatment-resistant depression
Publicado: (2021)

The role of intranasal esketamine in treatment-resistant depression
por: Fraga, A., et al.
Publicado: (2021)

Deprescribing in older people: helpful tools and proton pump inhibitors
Publicado: (2020)

Myeloid Sarcoma: The Clinician's Point of View
por: Malagola, M., et al.
Publicado: (2011)

From the nurses view point
por: Saini, Radha, et al.
Publicado: (2013)

Indigestion Leads to Depression: Avicenna's Point of View
por: Motavasselian, Malihe, et al.
Publicado: (2014)

Cranial Gravitational (Falling) Bullet Injuries: Point of View
por: Abdali, Husain A., et al.
Publicado: (2018)

The Patient's Point of View
por: Richmond, Eva
Publicado: (1910)

The Patient's Point of View
por: Richmond, Eva
Publicado: (1910)

Sex selection from Islamic point of view
por: Dezhkam, Lotfollah, et al.
Publicado: (2014)

Cardiotonic Drugs from the Avicenna’s Point of View
por: GHORBANI, Fariba, et al.
Publicado: (2015)

Esketamine for treatment resistant depression: a trick of smoke and mirrors?
por: Gastaldon, C., et al.
Publicado: (2019)

The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
por: Pepe, Maria, et al.
Publicado: (2023)

Urothelial toxicity of esketamine in the treatment of depression
por: Findeis, Hannelore, et al.
Publicado: (2020)

From the Patient's Point of View
Publicado: (1913)

Pyridoxine dependent epilepsies: new therapeutical point of view
por: Falsaperla, Raffaele, et al.
Publicado: (2017)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
por: Hernandez Huerta, D., et al.
Publicado: (2022)

Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
por: Rognoni, Carla, et al.
Publicado: (2023)

Esketamine for treatment‑resistant depression: A review of clinical evidence (Review)
por: Vasiliu, Octavian
Publicado: (2023)

Early real-life evaluation of the efficacy of esketamine in resistant depressive disorder
por: Faisant, S., et al.
Publicado: (2022)

Epidemiological research on cancers by cancer registries: A view point
por: Krishnatreya, Manigreeva
Publicado: (2015)

From a "Resident's" Point of View
Publicado: (1903)

Some Points of View of the Medical Profession
Publicado: (1912)

On the occasion of world hypertension day 2014: A nephrology point of view
por: Nasri, Hamid, et al.
Publicado: (2014)

COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view
por: Vitiello, Antonio, et al.
Publicado: (2021)

Transoral endoscopic thyroidectomy vestibular approach (TOETVA): pioneers's point of view
por: Bertelli, Antonio Augusto Tupinambá, et al.
Publicado: (2021)

Esketamine combined with sevoflurane anaesthesia for transurethral resection of the prostate in ankylosing spondylitis with severe thoracolumbar kyphoscoliosis: a case report and literature review
por: Gu, Xiaoling, et al.
Publicado: (2022)

Effectiveness and Tolerability of Intranasal Esketamine in Treatment-Resistant Depression: Report of Two Clinical Cases
por: Mercado-Rodríguez, A., et al.
Publicado: (2023)

Esketamine: A Drug to Treat Resistant Depression That Brings More Questions Than Answers
por: Mischel, Nicholas A., et al.
Publicado: (2021)

Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder
por: Veraart, J.K.E., et al.
Publicado: (2023)

Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France
por: Wattinne, E. Gaudre, et al.
Publicado: (2021)

Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
por: Salahudeen, Mohammed S, et al.
Publicado: (2020)

Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
por: Degerlund Maldi, Kinza, et al.
Publicado: (2021)

Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review
por: Sapkota, Alisha, et al.
Publicado: (2021)

Multiple Small Bowel Intussusceptions Caused by Kaposi's Sarcoma: The Radiologist's Point of View
por: Afonso, P Diana, et al.
Publicado: (2011)

Growth hormone treatment for adults with Prader-Willi syndrome: another point of view
por: Hirsch, Harry J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ke2ibdoern69t57g271o4ta0fg